BMN 110 Phase 3B in Australian Patients

Mucopolysaccharidosis IVA (Morquio A Syndrome) Clinical Trial

— MOR-AUS  

Official title:

A Multicenter Open-Label, Phase 3B Study to Evaluate the Efficacy and Safety of BMN 110 in Australian Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01966029
• Other study ID #: 110-502
• Status: Completed
• Phase: Phase 3
• Start date: July 2013
• Est. completion date: December 2016

Study information

• Verified date: September 2019
• Source: BioMarin Pharmaceutical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is currently no treatment for MPS IVA other than supportive care for the clinical manifestations of the disease. Enzyme replacement therapy (ERT) with BMN 110 to replace the deficient GALNS is a potential new treatment option for MPS IVA patients. BMN 110, containing recombinant human GALNS (rhGALNS) developed by BioMarin is expected to reduce the progressive, pathologic accumulation of KS, and improve signs and symptoms of the disease.

The objective of this Phase 3B open label study (110-502) will be to evaluate the safety and tolerability of 2.0 mg/kg/week (qw) of BMN 110 in Australian patients with MPS IVA. In addition, a number of secondary and tertiary efficacy endpoints will also be investigated. The dose and regimen of BMN 110 have been selected on the basis of data from a Phase 1/2 clinical study with BMN 110, nonclinical and in vitro studies with BMN 110, and clinical and nonclinical data from other enzyme replacement therapies.

Extension Phase is included per amendment dated 10Mar 2014: To provide patients enrolled in the Initial Phase access to BMN 110 until commercial product becomes available in Australia and continue to assess long-term safety

Description:

STUDY DESIGN AND PLAN: This is a multicenter, open-label Phase 3B study designed to evaluate the safety and efficacy of BMN 110 in Australian patients with MPS IVA. Approximately 10 patients in Australia with a confirmed diagnosis of MPS IVA will be enrolled in this study. Eligible patients will receive weekly infusion of BMN 110 2.0 mg/kg until BMN 110 becomes commercially available in Australia.

Screening [Week -4]. After obtaining informed consent, information on demographics, concomitant medication(s) use and medical history (including pre-study growth data) will be collected; blood will be drawn for confirming MPS IVA diagnosis by enzymatic test (when applicable); and, blood and urine for clinical laboratory tests will be collected. Electrocardiogram (ECG), routine physical examination including standard neurological examination, vital signs; and cervical spine (flexion-extension) imaging by either radiographs, or a Magnetic Resonance Imaging (MRI) or CT scan may be collected during Screening visit. Adverse Events (AEs)/Serious Adverse Events (SAEs) will also be monitored and collected.

Baseline Visit [Week 1, Day -1]. Upon confirmation of eligibility by confirmed diagnosis of MPS IVA by enzymatic test, negative pregnancy tests at Baseline (in women of childbearing age) and medical history, patients will be enrolled in the study and will complete following assessments: urine KS and urine creatinine, vital signs, routine physical examination including standard neurological examination, body weight (for verifying dose), clinical laboratory assessments, immunogenicity tests, ECG, 6MW test, 3MSC test and RFT will be performed and AEs/SAEs and concomitant medication use will be collected. In addition, anthropometric parameters (including height) will be measured, pain assessment test (Adolescent Pediatric Pain Tool [APPT], pain tool in children, adolescents, and adults) will be administered; and PedsQL (QOL questionnaire for pediatric patients) or SF-36 (QOL questionnaire for adult patients) questionnaire will also be completed during this visit. Patients who have abnormal overnight pulse oximetry readings will be assessed for sleep apnea, the results of which will be calculated using the Apnea-Hypopnea Index (AHI) at Baseline, Week 25, Week 49 and ETV.

Treatment Visit 1 [Week 1, Day 1]. Patients will receive the first dose of BMN 110 by intravenous (IV) infusion. Assessments on Day 1 will include vital signs, routine physical examination including standard neurological examination, and concomitant medication use and AEs/SAEs. All assessments will be performed prior to treatment, except AEs/SAEs which are collected continuously throughout the study. Immunogenicity lab tests are completed only in the event of an Infusion Associated Reaction.

Treatment Visits [Weeks 2-48]. Patients will be treated weekly with BMN 110 for 48 weeks. Prior to each weekly treatment, patients will have vital signs and routine physical examination including standard neurological examination. Concomitant medications and AEs/SAEs are collected at every visit. Body weight will be determined every 4 weeks after the Day -1 visit to confirm dose volume. Immunogenicity lab tests are completed only in the event of an Infusion Associated Reaction.

Efficacy Assessment Visits [Weeks 25 and 49]. The following data will be collected during weeks 25 and 49: clinical laboratory tests, urine KS and creatinine levels, immunogenicity test, ECG, 6MW test, 3MSC test, RFTs and anthropometric measurements. The patients will also complete the APPT test,and PedsQL or SF-36 questionnaire (as appropriate). Patients who have abnormal overnight pulse oximetry readings will be assessed for sleep apnea. Immunogenicity lab tests are completed only in the event of an Infusion Associated Reaction.

Additional Safety Assessment during Week 49 Visit. In addition to the efficacy and safety assessments listed above, cervical spine radiographs (flexion-extension) or MRI or CT scan will also be collected during the Week 49 visit.

Extension Phase [Required Safety and Recommended Efficacy Assessments]: Treatment Visits Patients will be treated weekly with BMN110 starting at week 49, following completion of all applicable efficacy assessments, until BMN110 becomes commercially available in Australia. Patients will have vital signs, concomitant medications and AEs/SAEs collected at every visit. Additional blood samples for total IgE and drug specific IgE testing will be drawn and analyzed for patients who experience a severe IAR, experience an IAR requiring cessation of infusion, anaphylaxis or a serious hypersensitivity event.

Safety Assessments: Treatment Visits [Every 4 weeks]. Body weight will be obtained every 4 weeks after the Day 1 visit to confirm dose volume. Treatment Visits [Every 24 weeks]. In addition to the assessments performed at weekly treatment visits, the patients will undergo pregnancy test (as appropriate).

Efficacy Assessments [Recommended every 24 weeks starting with Week 73]: Routine physical examination including standard neurological examination, clinical laboratory assessments, urine KS and creatinine levels, ECG, 6MW test, 3MSC test, RFTs and anthropometric measurements. The patients will also complete the APPT test, and PedsQL or SF-36 questionnaire (as appropriate), cervical spine imaging and sleep apnea test (if applicable). Patients who have abnormal overnight pulse oximetry readings will be assessed for sleep apnea.

End of Study Visit (EOS). The patients will be monitored for AEs and SAEs for up to 30 days post drug infusion. During Week 53 the EOS Visit, patients will be evaluated for AEs/SAEs and will have vital signs taken, routine physical examination including standard neurological examination will be performed, and information on concomitant medication use will be collected.

Patient withdrawal: Patients may withdraw voluntarily from receiving BMN 110 at any time, in which case they will be encouraged to continue to undergo study assessments. Data from such patients will be utilized for further characterization of the natural progression of MPS IVA. Patients may also withdraw entirely from study participation at any time.

Safety The study period during which all non-serious AEs and SAEs will be reported begins after informed consent is obtained and through 30 days after the last study visit or 30 days after the last drug infusion, whichever comes first. Starting on the first Screening Day and continuing through the end of the study or Early Termination Visit , AEs/SAEs will be monitored and recorded, and routine physical examination including standard neurological examination will be conducted in all patients. During the Initial Phase, routine physical examination including standard neurological examination will be conducted in all patients. During the Extension phase, physical examinations including neurologic examinations are recommended, but not required.

Some patients may experience infusion associated reactions (IARs) associated with the administration of study drug, thus it will be required that prophylactic antihistamine will be administered prior to each study drug infusion. Antipyretic pretreatment may be given at the Investigator's discretion. The internal Data Monitoring Committee (DMC) will monitor the safety of BMN 110 in patients and may review any severe or serious IARs that occur in patients during the study until approval from the United States Food and Drug Administration or the European Medicines Agency to commercialize BMN 110 is received. Vital signs will be measured just before, during, and immediately following the study drug infusion. Adverse events and changes in concomitant medication Safety assessments will be performed throughout the study. Physical examinations including neurological examination will be performed at Screening and all visits up to and including the Week 49 Visit.

Radiographs (flexion-extension) or MRI or CT scans of the cervical spine are required at Screening and at Week 49. Clinical laboratory tests, Electrocardiograms (ECG) are required at Screening, Baseline, Weeks 25 and 49 Visits. Blood samples will be collected at Baseline, Weeks 25 and 49 for TAb and NAb testing. NAb will not be performed if TAb is negative. Samples for Total IgE will be collected at Baseline and stored for testing. For patients who experience a severe infusion associated reaction (IAR), experience an IAR requiring cessation of infusion, anaphylaxis or a serious hypersensitivity event, shortly after cessation of the infusion, the Baseline total IgE sample will be analyzed and additional blood samples for total IgE and drug-specific IgE testing will be drawn and run. Immediate testing for total IgE will be taken shortly after cessation of the study drug infusion. Drug-specific IgE will also be tested, but must be collected no sooner than 8 hours post infusion and no later than just before the next scheduled infusion the following week due to rhGALNS interference with the detection assay. A sample taken the day after the IAR, anaphylactic or serious hypersensitivity event would be preferred but may not be practical. If the sample is positive, the extra volume of serum may be used to further characterize the drug-specific IgE assay. As patients may experience hypersensitivity reactions associated with the administration of BMN 110, all patients will be pretreated with an appropriate dose of antihistamine medication approximately 30 minutes to 1 hour prior to infusion. Antipyretic medications may also be given at the discretion of the Investigator. On infusion days, vital signs will be measured at a minimum of: immediately before (less than 30 minutes) the infusion, every 30 minutes for the first hour of the infusion, every hour for the remainder of the infusion, and immediately (less than 30 minutes) after the infusion. Patients will also be monitored by continuous pulse oximetry during infusion and for at least 60 minutes after the infusion is completed. AEs/SAEs and changes in concomitant medication will be recorded throughout the study. AEs/SAEs will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: December 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Diagnosed with MPS IVA as confirmed by a documented GALNS enzymatic test (GALNS activity in affected range, beta-galactosidase and a second lysosomal sulfatase activity within normal range).

2. Age 12 months or older.

3. Willing and able to provide written, signed informed consent. Or, in the case of patients under the age of 18 (or other age as defined by regional law or regulation), provide written assent (if required) and have written informed consent, signed by a legally authorized representative, after the nature of the study has been explained, and prior to performance of research-related procedures.

4. If sexually active, must be willing to use an acceptable method of contraception while participating in the study.

5. If female, and of childbearing potential, must have a negative pregnancy test at Baseline and be willing to have additional pregnancy tests done during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy. Childbearing potential will be assessed by the investigator.

Exclusion Criteria:

1. Previous treatment with BMN 110.

2. Has known hypersensitivity to any of the components of BMN 110.

3. Major surgery within 3 months prior to study entry or planned major surgery during the 48-week treatment period.

4. Prior bone marrow transplant (BMT) or hematopoietic stem cell transplant (HSCT).

5. Is pregnant or breastfeeding at Baseline, or planning to become pregnant (self orpartner) at any time during the study. Patients who become pregnant during the study will be discontinued from the study.

6. Has used any investigational product, or investigational medical device, within 30 days prior to Baseline; or is required to use any investigational agent prior to completion of all scheduled study assessments.

7. Has a concurrent disease or condition, including but not limited to, symptomatic cervical spine instability, clinically significant and/or progressive spinal cord compression, or severe cardiac disease that would interfere with study participation, or pose a safety risk, as determined by the Investigator.

8. Has any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study.

Related Conditions & MeSH terms

• Mucopolysaccharidoses
• Mucopolysaccharidosis IVA (Morquio A Syndrome)
• Syndrome

Intervention

Drug:
• BMN 110
All pateints receive treatment with BMN 110

Locations

Country	Name	City	State
Australia	Pain and Anaesthesia Research Clinic, Royal Adelaide Hospital	Adelaide
Australia	Lady Cilento Children's Hospital (previous: Royal Children's Hospital)	Brisbane	Queensland
Australia	Murdoch Childrens Research Institute and Royal Children's Hospital	Melbourne	Victoria
Australia	Princess Margaret Hospital for Children	Perth	Western Australia
Australia	Children's Hospital at Westmead	Westmead	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
BioMarin Pharmaceutical

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Analysis	The analyses of safety will include all patients who receive any study drug. All safety data will be summarized descriptively. All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). The incidence of AEs will be summarized by System Organ Class (SOC), Preferred Term (PT), relationship to study drug, and severity. Patient listings will be provided for SAEs, deaths, and AEs leading to study drug discontinuation, or study withdrawals. All AE summaries will include only treatment-emergent AEs (TEAEs) reported during the study period (AEs that occur after the first study drug infusion). Infusion-associated AEs will be summarized by SOC, PT and severity.; The following safety measures will be summarized descriptively: concomitant medications, clinical laboratory tests, vital signs, ECGs, immunogenicity results, analgesic medication use, results from routine physical examinations (including standard neurologic examinations), and cervical spine imaging.	The study period during which all non-serious AEs and SAEs will be reported begins after informed consent is obtained and through 30 days after the last study visit or 30 days after the last drug infusion, whichever comes first.
Secondary	Efficacy Analysis	Efficacy assessments and procedures are the duplicate endurance testing (6MW and 3MSC tests) at Baseline and at week 25 and 49. Samples for urine KS and urine creatinine will be collected at Baseline and every 24 weeks.; Anthropometric measurements, including standing height, length, sitting height, knee height (as clinically indicated), head circumference and weight, will be taken at Baseline and every 24 weeks.; Respiratory function tests (RFTs) for assessment of forced expiratory volume for 1 second (FEV1), forced inspiratory vital capacity (FIVC), forced vital capacity (FVC), and maximum voluntary ventilation (MVV) will be performed at Baseline and Weeks 25 and 49. APPT (pain assessment tool), and the PedsQL (Pediatric Quality of Life Inventory) or SF-36® (QOL questionnaire for adult patients) will be done at Baseline, Week 25, and Week 49. The Sleep Apnea Test will be done at Baseline, Week 25 and Week 49, if applicable.	Baseline, Week 25, Week 49 or Early Termination Visit
Secondary	Efficacy Analysis (recommended)	The efficacy assessments as mentioned in Efficacy Analysis 2 above are all recommended in the Extension Phase per the protocol amendment dated 17Mar 2014	by Week 24, Week 52 and Early Termination Visit during Extension Phase